Thu, February 2, 2023
Wed, February 1, 2023
Tue, January 31, 2023

Joon Lee Maintained (TSHA) at Strong Buy with Decreased Target to $4 on, Feb 1st, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -with-decreased-target-to-4-on-feb-1st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joon Lee of Truist Securities, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Strong Buy with Decreased Target from $15 to $4 on, Feb 1st, 2023.

Joon has made no other calls on TSHA in the last 4 months.



There are 3 other peers that have a rating on TSHA. Out of the 3 peers that are also analyzing TSHA, 2 agree with Joon's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $3 on, Friday, January 27th, 2023
  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $3 on, Wednesday, November 9th, 2022


This is the rating of the analyst that currently disagrees with Joon


  • Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023

Publication Contributing Sources